Alnylam Pharmaceuticals, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2016 | -44.6% | -44.6% | -32.5% |
| FY2017 | -27.8% | -27.8% | -24.6% |
| FY2018 | -58.5% | -58.5% | -48.4% |
| FY2019 | -61.6% | -61.6% | -37.0% |
| FY2020 | -84.5% | -84.5% | -25.2% |
| FY2021 | -145.0% | -145.0% | -23.4% |
| FY2022 | 714.9% | 714.9% | -31.9% |
| FY2023 | 199.5% | 199.5% | -11.5% |
| FY2024 | -414.6% | -414.6% | -6.6% |
| FY2025 | 39.8% | 39.8% | 6.3% |